Skip to main content

Bariatric Surgery Linked to Improved IBD Outcomes in Patients With Obesity

By Elana Gotkine HealthDay Reporter

Medically reviewed by Drugs.com

via HealthDay

THURSDAY, Aug. 21, 2025 -- For patients with inflammatory bowel disease and obesity, bariatric surgery is associated with improved inflammatory bowel disease-related outcomes, according to a study published online July 22 in BJS Open.

Erik Stenberg, M.D., from Örebro University in Sweden, and colleagues conducted a nationwide cohort study involving all adult patients in Sweden between 2007 and 2020 with obesity and inflammatory bowel disease. A two-stage process was used to match those undergoing bariatric surgery with those who were not.

A total of 798 patients with inflammatory bowel disease and obesity were included: 399 underwent bariatric surgery and 399 did not. The researchers found that the composite primary end point (inflammatory bowel disease-related hospitalization, initiation of corticosteroid therapy, immunomodulation, commencement of a new targeted therapy, or major inflammatory bowel disease-related surgery) occurred in 201 and 226 patients who had surgery and did not have surgery, respectively (incidence rate, 11.9 and 15.1 per 100 person-years), corresponding to a hazard ratio of 0.66 for those undergoing bariatric surgery.

"Bariatric surgery was associated with a lower risk of worsening IBD. The risk was reduced both in ulcerative colitis and in Crohn's disease," the authors write. "A similar tendency was seen after sleeve gastrectomy as well as Roux-en-Y gastric bypass, but the results were statistically significant only after Roux-en-Y gastric bypass surgery."

Several authors disclosed ties to the pharmaceutical industry.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Posted August 2025

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.